United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) Director Raymond Dwek sold 3,000 shares of United Therapeutics stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $285.57, for a total transaction of $856,710.00. Following the completion of the sale, the director now owns 1,750 shares of the company's stock, valued at approximately $499,747.50. The trade was a 63.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Raymond Dwek also recently made the following trade(s):
- On Monday, April 14th, Raymond Dwek sold 3,000 shares of United Therapeutics stock. The stock was sold at an average price of $285.16, for a total value of $855,480.00.
- On Monday, April 7th, Raymond Dwek sold 4,000 shares of United Therapeutics stock. The shares were sold at an average price of $284.55, for a total value of $1,138,200.00.
United Therapeutics Price Performance
Shares of United Therapeutics stock opened at $292.82 on Wednesday. The company's 50 day moving average price is $313.33 and its two-hundred day moving average price is $347.74. The firm has a market capitalization of $13.15 billion, a P/E ratio of 12.86, a P/E/G ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a fifty-two week low of $233.28 and a fifty-two week high of $417.82.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. During the same period last year, the company earned $4.36 EPS. On average, analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current year.
Analyst Ratings Changes
A number of research analysts recently commented on UTHR shares. HC Wainwright restated a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. JPMorgan Chase & Co. decreased their target price on shares of United Therapeutics from $357.00 to $355.00 and set an "overweight" rating on the stock in a report on Monday. UBS Group boosted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 17th. Finally, Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective for the company in a research report on Monday. Three analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $395.67.
Read Our Latest Stock Analysis on United Therapeutics
Institutional Investors Weigh In On United Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in UTHR. Signaturefd LLC boosted its holdings in United Therapeutics by 4.7% in the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock valued at $234,000 after acquiring an additional 30 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of United Therapeutics by 2.8% in the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock valued at $385,000 after purchasing an additional 30 shares during the last quarter. Anchor Investment Management LLC increased its position in shares of United Therapeutics by 12.0% during the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after buying an additional 30 shares during the period. Great Lakes Advisors LLC raised its stake in United Therapeutics by 1.6% during the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock worth $697,000 after buying an additional 31 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its holdings in United Therapeutics by 0.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock valued at $3,214,000 after buying an additional 33 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
